Toggle Health Problems and D

Might Vitamin D be the fountain of youth – June 2013

Scientific overview of hormone treatment used for rejuvenation

Fertility and Sterility. Volume 99, Issue 7 , Pages 1807-1813, June 2013
John E. Morley, M.B., B.Ch. morley at slu.edu
Division of Geriatric Medicine, Saint Louis University School of Medicine, St. Louis, Missouri

A search for a hormonal fountain of youth has been hotly pursued over the last century, predominately by those who wish to market hormones to a gullible public. There is little or no benefit of hormone replacement in persons who do not have a hormone deficiency. Overall, the present state of the art suggests that the findings have been disappointing.

In persons who fail to get adequate sunlight, and therefore have low vitamin D levels, vitamin D replacement appears to have positive effects, including decreasing mortality.

Testosterone in hypogonadal males has a number of positive effects such as improving libido and erectile capacity, increasing strength and bone mineral density, and perhaps having a small effect on cognition. These effects need to be balanced against long-term side effects, the evidence for which studies are lacking.

There is little evidence to recommend DHEA, pregnenolone, growth hormone, ghrelin, or melatonin to older persons.

Overall, exercise, adequate exposure to sunlight, and adequate dietary protein appear to have at least as positive an effect as any of the hormones being used to rejuvenate older persons.

See also VitaminDWiki

References from this study

Morley JE. A brief history of geriatrics. J Geron Biol Sci Med Sci. 2004;59:1132–1152

Horani MH, Morley JE. Hormonal fountains of youth. Clin Geriatr Med. 2004;20:275–292 Full-Text PDF (252 KB)

Khaw KT, Wareham N, Bingham S, Welch A, Luben R, Day N, et al. Combined impact of health behaviours and mortality in men and women: the EPIC-Norfolk prospective population study. PLoS Med. 2008;5:e12

Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: An updated systematic review and meta-analysis. Am J Clin Nutr. 2010;92:1189–1196

Yamada M, Arai H, Sonoda T, Aoyama T. Community-based exercise program is cost-effective by preventing care and disability in Japanese frail older adults. J Am Med Dir Assoc. 2012;13:507–511 Full-Text PDF (313 KB)

Snyder A, Colvin B, Gammack JK. Pedometer use increases daily steps and functional status in older adults. J Am Med Dir Assoc. 2011;12:590–594 Full-Text PDF (131 KB)

Lam LC, Chau RC, Wong BM, Fung AW, Tom CW, Leung GT, et al. A 1-year randomized controlled trial comparing mind body exercise (Tai Chi) with stretching and toning exercise on cognitive function in older Chinese adults at risk of cognitive decline. J Am Med Dir Assoc. 2012;13:568.e15–568.e20 Full-Text PDF (257 KB)

Valenzuela T. Efficacy of progressive resistance training interventions in older adults in nursing homes: a systematic review. J Am Med Dir Assoc. 2012;13:418–428 Full-Text PDF (301 KB)

Singh NA, Quine S, Clemson LM, Williams EJ, Williamson DA, Stavrinos TM, et al. Effects of high-intensity progressive resistance training and targeted multidisciplinary treatment of frailty on mortality and nursing home admissions after hip fracture: a randomized controlled trial. J Am Med Dir Assoc. 2012;13:24–30 Full-Text PDF (168 KB)

Brienesse LA, Emergson MN. Effects of resistance training for people with Parkinson's disease: a systematic review. J Am Med Dir Assoc. 2013;14:236–241 Full-Text PDF (158 KB)

Rouge Bugat ME, Cestac P, Oustric S, Vellas B, Nourhashemi F. Detecting frailty in primary care: a major challenge for primary care physicians. J Am Med Dir Assoc. 2012;13:669–672 Full-Text PDF (783 KB)

Hoogendijk EO, van Hout HP. Investigating measurement properties of the Groningen Frailty Indicator: a more systematic approach is needed. J Am Med Dir Assoc. 2012;13:757;Author reply 757–58 Full-Text PDF (75 KB)

Peters LL, Boter H, Buskens E, Slaets JP. Measurement properties of the Groningen Frailty Indicator in home-dwelling and institutionalized elderly people. J Am Med Dir Assoc. 2012;13:546–551 Full-Text PDF (147 KB)

Morley JE. The magic of exercise. J Am Med Dir Assoc. 2008;9:375–377 Full-Text PDF (69 KB)

Cruz-Jentoft AJ. Perspective: protein and exercise for frailty and sarcopenia: still learning. J Am Med Dir Assoc. 2013;14:69–71 Full-Text PDF (68 KB)

Chou CH, Hwang CL, Wu YT. Effect of exercise on physical function, daily living activities, and quality of life in the frail older adults: a meta-analysis. Arch Phys Med Rehabil. 2012;93:237–244 Full-Text PDF (1192 KB)

Van Wetering CR, Hoogendoorn M, Broekhuizen R, Geraerts-Kerris GJ, De Munck DR, Rutten-van Mölken MP, et al. Efficacy and costs of nutritional rehabilitation in muscle-wasted patients with chronic obstructive pulmonary disease in a community-based setting: a prespecified subgroup analysis of the INTERCOM trial. J Am Med Dir Assoc. 2010;11:179–187 Full-Text PDF (265 KB)

Malafarina V, Uriz-Otano F, Iniesta R, Gil-Guerrero L. Effectiveness of nutritional supplementation on muscle mass in treatment of sarcopenia in old age: a systematic review. J Am Med Dir Assoc. 2013;14:10–17 Full-Text PDF (209 KB)

Morley JE, Argiles JM, Evans WJ, Bhasin S, Cella D, Deutz NE, et al. Society for Sarcopenia, Cachexia, and Wasting Disease Nutritional recommendations for the management of sarcopenia. J Am Med Dir Assoc. 2010;11:391–396 Full-Text PDF (102 KB)

Morley JE. Do frail older persons need more protein?. J Am Med Dir Assoc. 2012;13:667–668 Full-Text PDF (98 KB)

Tieland M, van de Rest O, Dirks ML, van der Zwaluw N, Mensink M, van Loon LJ, et al. Protein supplementation improves physical performance in frail elderly people: a randomized, double-blind, placebo-controlled trial. J Am Med Dir Assoc. 2012;13:720–726 Full-Text PDF (225 KB)

Tieland M, Dirks ML, van der Zwaluw N, Verdijk LB, van de Rest O, de Groot LC, et al. Protein supplementation increases muscle mass gain during prolonged resistance-type exercise training in frail elderly people: a randomized, double-blind, placebo-controlled trial. J Am Med Dir Assoc. 2012;13:713–719 Full-Text PDF (288 KB)

Mir F, Zafar F, Morley JE. Anorexia of aging: can we decrease protein energy undernutrition in the nursing home?. J Am Med Dir Assoc. 2013;14:77–79 Full-Text PDF (118 KB)

Neelemaat F, Bosmans JE, Thijs A, Seidell JC, van Bokhorst-de van de Schueren MO. Post-discharge nutritional support in malnourished elderly individuals improves functional limitations. J Am Med Dir Assoc. 2011;12:295–301 Full-Text PDF (144 KB)

Morley JE. Weight loss in older persons: new therapeutic approaches. Curr Pharm Des. 2007;13:3637–3647

Morley JE, Chahla E, Alkaade S. Antiaging, longevity and calorie restriction. Curr Opin Clin Nutr Metab Care. 2010;13:40–45

Morley JE. Undernutrition: a major problem in nursing homes. J Am Med Dir Assoc. 2011;12:243–246 Full-Text PDF (78 KB)

Shah K, Armamento-Villareal R, Parimi N, Chode S, Sinacore DR, Hilton TN, et al. Exercise training in obese older adults prevents increase in bone turnover and attenuates decrease in hip BMD induced by weight loss despite decline in bone-active hormones. J Bone Miner Res. 2011;26:2851–2859

Perry HM, Horowitz M, Morley JE, Patrick P, Vellas B, Baumgartner R, et al. Longitudinal changes in serum 25-hydroxyvitamin D in older people. Metab Clin Exper. 1999;48:1028–1032

Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53–58

Islam T, Peiris P, Copeland RJ, El Zoghby M, Peiris AN. Vitamin D: lessons from the veterans population. J Am Med Dir Assoc. 2011;12:257–262 Full-Text PDF (84 KB)

Mckinney JD, Bailey BA, Garrett LH, Peiris P, Manning T, Peiris AN. Relationship between vitamin D status and ICU outcomes in veterans. J Am Med Dir Assoc. 2011;12:208–211

Gaddipati VC, Bailey BA, Kuriacose R, Copeland RJ, Manning T, Peiris AN. The relationship of vitamin D status to cardiovascular risk factors and amputation risk in veterans with peripheral arterial disease. J Am Med Dir Assoc. 2011;12:58–61 Full-Text PDF (81 KB)

Demontiero O, Herrmann M, Duque G. Supplementation with vitamin D and calcium in long-term care residents. J Am Med Dir Assoc. 2011;12:190–194 Full-Text PDF (98 KB)

Morley JE. Vitamin D redux. J Am Med Dir Assoc. 2009;10:591–592 Full-Text PDF (63 KB)

Morley JE. Developing novel therapeutic approaches to frailty. Curr Pharm Design. 2009;29:3384–3395

Rejnmark L, Avenell A, Masud T, Anderson F, Meyer HE, Sanders KM, et al. Vitamin D with calcium reduces mortality: patient level pooled analysis of 70,528 patients from eight major vitamin D trials. J Clin Endocrinol Metab. 2012;97:2670–2681

Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev. 2011;CD007470

Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168:1629–1637

Murad MH, Elamin KB, Elnour A, Elamin MB, Alkatib AA, Fatourechi MM, et al. Clinical review. The effect of vitamin D on falls: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96:2997–3006

Bergman GJ, Fan T, McFetridge JT, Sen SS. Efficacy of vitamin D3 supplementation in preventing fractures in elderly women: a meta-analysis. Curr Med Res Opin. 2010;26:1193–1201

Bishoff-Ferrari HA, Willett WC, Wong JB, Stuck AE, Staehelin HB, Orav EJ, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med. 2009;169:551–561

Von Haehling S, Morley JE, Anker SD. From muscle wasting to sarcopenia and myopenia: Update 2012. J Cachexia Sarcopenia Muscle. 2012;3:213–217

Hewison M. Vitamin D and immune function: autocrine, paracrine or endocrine?. Scand J Clin Lab Invest Suppl. 2012;243:92–102

Khan H, Kunutsor S, Franco OH, Chowdhury R. Vitamin D, type 2 diabetes and other metabolic outcomes: a systematic review and meta-analysis of prospective studies. Proc Nutr Soc. 2013;72:89–97

Riphagen IJ, van der Veer E, Muskiet FA, DeJongste MJ. Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D. Curr Med Res Opin. 2012;28:1247–1252

Luong KV, Nguyen LT. The beneficial role of vitamin D in Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2011;26:511–520

Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren , et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male. 2009;12:5–12

Perry HM, Miller DK, Patrick P, Morley JE. Testosterone and leptin in older African-American men: relationship to age, strength, function, and season. Metabolism. 2000;49:1085–1091 Full-Text PDF (76 KB)

Morley JE, Patrick P, Perry HM. Evaluation of assays available to measure free testosterone. Metabolism. 2002;51:554–559 Full-Text PDF (137 KB)

Tajar A, Huhtaniemi IT, O'Neill TW, Finn JD, Pye SR, Lee DM, et al. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012;97:1508–1516

Matsumoto AM. Fundamental aspects of hypogonadism in the aging male. Rev Urol. 2003;(5 Suppl):S3–S10

Huhtaniemi IT, Tajar A, Lee DM, O'Neill TW, Finn JD, Bartfai G, et al. Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men. Eur J Endocrinol. 2012;166:983–991

Bhasin S, Pencina M, Jasuja GK, Travison TG, Coviello A, Orwoll E, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011;96:2430–2439

Morley JE, Melmed S. Gonadal dysfunction in systemic disorders. Metabolism. 1979;28:1051–1073

Morley JE. Anabolic steroids and frailty. J Am Med Dir Assoc. 2010;11:533–536 Full-Text PDF (117 KB)

Hyde Z, Flicker L, Almeida OP, Hankey GJ, McCaul KA, Chubb SA, et al. Low free testosterone predicts frailty in older men: the health in men study. J Clin Endocrinol Metab. 2010;95:3165–3172

Cawthon PM, Ensrud KE, Laughlin GA, Cauley JA, Dam TT, Barrett-Connor E, et al. Sex hormones and frailty in older men: the osteoporotic fractures in men (MrOS) study. J Clin Endocrinol Metab. 2009;94:3806–3815

Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation. 2007;226:2694–2701

Cummings-Vaughn LA, Malmstrom TK, Morley JE, Miller DK. Testosterone is not associated with mortality in older African-American males. Aging Male. 2011;14:132–140

Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93:68–75

Morley JE, Kaiser FE, Perry HM, Patrick P, Morley PMK, Stauber PM, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism. 1997;46:410–413 Full-Text PDF (406 KB)

Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97:2050–2058

Cesari M, Vellas B. Saropcenia: a novel clinical condition or still a matter for research?. J Am Med Dir Assoc. 2012;13:766–767 Full-Text PDF (100 KB)

Landi F, Liperoti R, Fusco D, Mastropaolo S, Quattrociocchi D, Proia A, et al. Sarcopenia and mortality among older nursing home residents. J Am Med Dir Assoc. 2012;13:121–126 Full-Text PDF (370 KB)

Morley JE, Abbatecola AM, Argiles JM, Baracos V, Bauer J, Bhasin S, et al. Society on Sarcopenia, Cachexia and Wasting Disorders Trialist Workshop Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc. 2011;12:403–409 Full-Text PDF (118 KB)

Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011;12:249–256 Full-Text PDF (132 KB)

Bauer JM, Kaiser MJ, Sieber CC. Sarcopenia in nursing home residents. J Am Med Dir Assoc. 2008;9:545–551

Rolland Y, Czerwinski S, Abellan van Kan G, Morley JE, Cesari M, Onder G, et al. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging. 2008;12:433–450

Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev. 1999;107:123–136

Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci. 2003;58:618–625

Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005;90:1502–1510

Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab. 2005;90:678–688

Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109–122

Srivinas-Shanker U, Roberts SA, Connelly MJ, O'Connell MD, Adams JE, Oldham JA, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95:639–650

Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc. 2010;58:1134–1143

Iellamo F, Volterrani M, Caminiti G, Karam R, Massaro R, Fini M, et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol. 2010;56:1310–1316 Full-Text PDF (272 KB)

Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009;54:919–927 Full-Text PDF (356 KB)

Chapman IM, Misvanathan R, Hammond AJ, Morley JE, Field JB, Tai K, et al. Effect of testosterone and a nutritional supplement, alone and in combination, on hospital admissions in undernourished older men and women. Am J Clin Nutr. 2009;89:880–889

Travison TG, Morley JE, Araujo AB, O'Donnell AB, McKinlay JB. The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab. 2006;91:2509–2513

Tariq SH, Haren MT, Kim MJ, Morley JE. Andropause: is the emperor wearing any clothes?. Rev Endocr Metab Disord. 2005;6:77–84

Spitzer M, Basaria S, Travison TG, Davda MN, Paley A, Cohen B, et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann Intern Med. 2012;157:681–691

Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone deficiency. Am J Med. 2011;124:578–587 Full-Text PDF (1411 KB)

Morley JE. Androgens and aging. Maturitas. 2011;38:61–71 Full-Text PDF (327 KB)

Mellström D, Johnell O, Ljunggren O, Eriksson AL, Lorentzon M, Mallmin H, et al. Free testosterone is an independent predictor of MBD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res. 2006;21:529–535

Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004;89:503–510

Morley JE, Kaiser F, Raum WJ, Perry HM, Flood JF, Jensen J, et al. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: Progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci USA. 1997;94:7537–7542

Chu LW, Tam S, Lee PW, Wong RL, Yik PY, Tsui W, et al. Bioavailable testosterone is associated with a reduced risk of amnestic mild cognitive impairment in older men. Clin Endocrinol (Oxf). 2008;68:589–598

Chu LW, Tam S, Wong RL, Yik PY, Song Y, Cheung BM, et al. Bioavailable testosterone predicts a lower risk of Alzheimer's disease in older men. J Alzheimers Dis. 2010;21:1335–1345

Morley JE, Farr SA, Kumar VB, Armbrecht HJ. The SAMP8 mouse: a model to develop therapeutic interventions for Alzheimer's disease. Curr Pharm Des. 2012;18:1123–1130

Farr SA, Price TO, Banks WA, et al. Effect of alpha-lipoic acid on memory, oxidation, and lifespan in SAMP8 mice. J Alzheimers Dis. 2012;32:447–455

Kumar VB, Farr SA, Flood JF, Kamlesh V, Franko M, Banks WA, et al. Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice. Peptides. 2000;21:1769–1775

Flood JF, Farr SA, Kaiser FE, La Regina M, Morley JE. Age-related decrease of plasma testosterone in SAMP8 mice—replacement improves age-related impairment of learning and memory. Physiol Beh. 1995;57:669–673

Cherrier MM. Testosterone effects on cognition in health and disease. Front Horm Res. 2009;37:150–162

Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab. 1997;82:3793–3796

Chahla EJ, Hayek ME, Morley JE. Testosterone replacement therapy and cardiovascular risk factors modification. Aging Male. 2011;14:83–90

Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60:1451–1457

Morley JE, Perry HM, Kevorkian RT, Patrick P. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas. 2006;53:424–429 Full-Text PDF (96 KB)

Morley JE. Should frailty be treated with testosterone?. Aging Male. 2011;14:1–3

Haring R, Xanthakis V, Coviello A, Sullivan L, Bhasin S, Wallaschofski H, et al. Clinical correlates of sex steroids and gonadotropins in men over the late adulthood: The Framingham Heart Study. Int J Androl. 2012;35:775–782

Tsujimura A, Matsumiya K, Takao T, Miyagawa Y, Takada S, Koga M, et al. Treatment with human chorionic gonadotropin for PADAM: a preliminary report. Aging Male. 2005;8:175–179

Burnett-Bowie SA, McKay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrniol Metab. 2009;94:4785–4792

Harman SM, Blackman MR. The effects of growth hormone and sex steroid on lean body mass, fat mass, muscle strength, cardiovascular endurance and adverse events in healthy elderly women and men. Horm Res. 2003;60(Suppl 1):121–124

Goel RM, Cappola AR. Dehydroepiandrosterone sulfate and postmenopausal women. Curr Opin Endocrinol Diabetes Obes. 2011;18:171–176

Regelson W, Colman C. The superhormone promise: nature's antidote to aging. New York: Pocket Books; 1997;

Baulieu EE, Thomas G, Legrain S, Lahlou N, Roger M, Debuire B, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge study to a sociobiomedical issue. Proc Natl Acad Sci USA. 2000;97:4279–4284

Percheron G, Hogrel JY, Denot-Ledunois S, Fayet G, Forette F, Baulieu EE, et al. Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial. Arch Intern Med. 2003;163:720–727

Baker WL, Karan S, Kenny AM. Effect of dehydroepiandrosterone on muscle strength and physical function in older adults: a systematic review. J Am Geriatr Soc. 2011;59:997–1002

Von Muhlen D, Laughlin GA, Kritz-Silverstein D, Bergstrom J, Bettencourt R. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial. Osteoporos Int. 2008;19:699–707

Weiss EP, Shah K, Fontana L, Lambert C, Holloszy JO, Villareal DT. Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone. Am J Clin Nutr. 2009;89:1459–1467

Flood JF, Morley JE, Roberts E. Pregnenolone sulfate enhances post-training memory processes when injected in very low doses into limbic system structures: the amygdala is by far the most sensitive. Proc Natl Acad Sci USA. 1995;92:10806–10810

Kritz-Silverstein D, von Muhlen D, Laughlin GA, Bettencourt R. Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well-Ness (DAWN) trial. J Am Geriatr Soc. 2008;56:1292–1298

Van Niekerk JK, Huppert FA, Herbert J. Salivary cortisol and DHEA: association with measures of cognition and well-being in normal older men, and effects of three months of DHEA supplementation. Psychoneuroendocrinology. 2001;26:591–612 Full-Text PDF (124 KB)

Grimley Evans J, Malouf R, Huppert F, van Niekerk JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people. Cochrane Database Syst Rev. 2006;CD006221

Barnhart KT, Freeman E, Grisso JA, Rader DJ, Sammel M, Kapoor S, et al. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health related quality of life. J Clin Endocrinol Metab. 1999;84:3896–3902

Finckh A, Berner JC, Aubry-Rozier B, So AK. A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. J Rheumatol. 2005;32:1336–1340

Arlt W, Callies F, Allolio B. DHEA replacement in women with adrenalin sufficiency—pharmacokinetics bioconversion and clinical effects on well-being, sexuality and cognition. Endocr Res. 2000;26:505–511

Hersch EC, Merriam GR. Growth hormone (GH)-releasing hormone and GH secretagogues in normal aging: Fountain of Youth or Pool of Tantalus?. Clin Interv Aging. 2008;3:121–129

Veldhuis JD. Aging and hormones of the hypothalamo-pituitary axis: gonadotropic axis in men and somatotropic axes in men and women. Ageing Res Rev. 2008;7:189–208

Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990;323:1–6

Cohn L, Feller AG, Draper MW, Rudman IW, Rudman D. Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF–1 concentrations. Clin Endocrniol (Oxf). 1993;39:417–425

Kaiser FE, Silver AJ, Morley JE. The effect of recombinant human growth hormone on malnourished older individuals. J Am Geriatr Soc. 1991;39:235–240

Urban RJ. Growth hormone and testosterone: anabolic effects on muscle. Horm Res Paediatr. 2011;76(Suppl 1):81–83

Sattler FR, Castaneda-Sceppa C, Binder EF, Schroeder ET, Wang Y, Bhasin S, et al. Testosterone and growth hormone improve body composition and muscle performance in older men. J Clin Endocrinol Metab. 2009;94:1991–2001

Fanciulli G, Delitala A, Delitala G. Growth hormone, menopause and ageing: no definite evidence for “rejuvenation” with growth hormone. Hum Reprod Update. 2009;15:341–358

Chaves VE, Junior FM, Bertolini GL. The metabolic effects of growth hormone in adipose tissue. Endocrine. 2013;

Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, et al. Systematic review: the safety and efficacy of growth hormone in the health elderly. Ann Intern Med. 2007;146:104–115

Blackman MR, Sorkin JD, Munzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. 2002;288:2282–2292

Taub DD, Murphy WJ, Longo DL. Rejuvenation of the aging thymus: growth hormone- and ghrelin-mediated signaling pathways. Curr Opin Pharmacol. 2010;10:408–424

Banks WA, Morley JE, Farr SA, Price TO, Ercal N, Vidaurre I, et al. Effects of a growth hormone-releasing hormone antagonist on telomerase activity, oxidative stress, longevity, and aging in mice. Proc Natl Acad Sci USA. 2010;107:22272–22277

Gaskin FS, Farr SA, Banks WA, Kumar VB, Morley JE. Ghrelin-induced feeding is dependent on nitric oxide. Peptides. 2003;24:913–918

Strasser F. Clinical application of ghrelin. Curr Pharm Des. 2012;18:4800–4812

White HK, Petrie CD, Landschulz W, MacLean D, Taylor A, Lyles K, et al. Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab. 2009;94:1198–1206

Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE, Clasey JL, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149:601–611

Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berdy , et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011;53:183–189 Full-Text PDF (305 KB)

Bubenik GA, Konturek SJ. Melatonin and aging: prospects for human treatment. J Physiol Pharmacol. 2011;62:13–19

van Geijlswijk IM, Korsilius HP, Smits MG. The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. Sleep. 2010;33:1605–1614

Ferguson SA, Rajaratnam SM, Dawson D. Melatonin agonists and insomnia. Expert Rev Neurother. 2010;10:305–318

Kim MJ, Morley JE. The hormonal fountains of youth: myth or reality?. J Endocrinol Invest. 2005;28(11 Suppl Proc):5–14

Short url = http://is.gd/VitD_Longevity